Novo Nordisk: more detailed results on Wegovy
(CercleFinance.com) - On Monday, Novo Nordisk unveiled more detailed results from its trial on the cardiovascular benefits of its anti-obesity drug Wegovy, which caused a stir over the summer.
In August, the Danish company reported that semaglutide 2.4 mg (Wegovy) reduced the risk of a major cardiovascular event by 20% over five years.
Novo says that the initial findings of this phase III trial, dubbed "Select", show that this statistically significant level of 20% was independent of the age, gender, ethnic origin and body mass index of the participants.
These initial findings were unveiled at the American Heart Association meeting and published at the same time in the New England Journal of Medicine.
Following these announcements, Novo Nordisk shares rose by over 3% on the Copenhagen Stock Exchange on Monday.
Copyright (c) 2023 CercleFinance.com. All rights reserved.